Get the Stockscreener App
29.31
0.37%
-0.11
After Hours:
29.31
Sionna Therapeutics Inc stock is traded at $29.31, with a volume of 404.04K.
It is down -0.37% in the last 24 hours and up +28.38% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$29.42
Open:
$29.68
24h Volume:
404.04K
Relative Volume:
1.73
Market Cap:
$1.29B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.21%
1M Performance:
+28.38%
6M Performance:
+272.43%
1Y Performance:
+0.00%
1-Day Range:
$28.89
$31.02
1-Week Range:
$24.65
$31.02
52-Week Range:
$7.255
$31.02
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
29.31 | 1.30B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
Sionna Therapeutics Inc Stock (SION) Latest News
Sionna Therapeutics Inc. stock trendline breakdown2025 Market WrapUp & Free Technical Confirmation Trade Alerts - newser.com
Relative strength of Sionna Therapeutics Inc. in sector analysisTrade Exit Report & Consistent Profit Trading Strategies - newser.com
Analyzing Sionna Therapeutics Inc. with multi timeframe chartsWeekly Trade Report & Community Verified Trade Alerts - newser.com
Is Sionna Therapeutics Inc. stock a safe haven assetJuly 2025 Update & AI Driven Stock Reports - newser.com
What analysts say about Sionna Therapeutics Inc stockReal-Time Stock Alerts & Free Stock Trading Workshops - earlytimes.in
Why hedge funds are buying Sionna Therapeutics Inc. stockQuarterly Profit Summary & AI Enhanced Trade Execution Alerts - newser.com
Sionna Therapeutics (NASDAQ:SION) Trading Up 6%What's Next? - MarketBeat
What indicators show strength in Sionna Therapeutics Inc.2025 Year in Review & Smart Money Movement Tracker - newser.com
Will Sionna Therapeutics Inc. bounce back from current support2025 Buyback Activity & Precise Buy Zone Tips - newser.com
What momentum indicators show for Sionna Therapeutics Inc. stockEntry Point & Long-Term Capital Growth Strategies - newser.com
Sionna Therapeutics (NASDAQ:SION) Receives "Sell (D)" Rating from Weiss Ratings - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 3.5% After Insider Selling - MarketBeat
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 11,800 Shares of Stock - MarketBeat
Only Mass. biotech to go public this year grows headcount 71% - NBC Boston
Sionna Therapeutics Inc. stock trend outlook and recovery pathPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - newser.com
Detecting price anomalies in Sionna Therapeutics Inc. with AIEntry Point & High Return Trade Guides - newser.com
Live market analysis of Sionna Therapeutics Inc.CPI Data & Free Community Supported Trade Ideas - newser.com
Using flow based indicators on Sionna Therapeutics Inc.Risk Management & Weekly High Return Stock Opportunities - newser.com
Multi factor analysis applied to Sionna Therapeutics Inc.July 2025 News Drivers & Expert-Curated Trade Recommendations - newser.com
Sionna Therapeutics (SION): Exploring Valuation After Recent 15% Share Price Climb - Sahm
Statistical indicators supporting Sionna Therapeutics Inc.’s strengthWeekly Trade Analysis & Weekly High Conviction Ideas - newser.com
Will Sionna Therapeutics Inc. stock deliver strong dividend growth2025 Macro Impact & Daily Entry Point Trade Alerts - newser.com
Sionna Therapeutics (NASDAQ:SION) Shares Gap Down Following Insider Selling - Defense World
How currency fluctuations impact Sionna Therapeutics Inc. stockMarket Trend Review & Smart Allocation Stock Reports - newser.com
Sionna Therapeutics director sells shares worth $2.37 million By Investing.com - Investing.com South Africa
Sionna Therapeutics (NASDAQ:SION) Shares Down 5.1% After Insider Selling - Defense World
Sionna Therapeutics director sells shares worth $2.37 million - Investing.com
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference - GlobeNewswire
Sionna Therapeutics Inc Stock (SION) Financials Data
There is no financial data for Sionna Therapeutics Inc (SION). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):